Prognostic factors for cellular therapies ‐ CART and allogeneic SCT ‐ in relapsed /refractory large B cell lymphoma (LBCL)

Saved in:
Bibliographic Details
Published in:Hematological oncology 2023-06, Vol.41 (S2), p.449-451
Main Authors: Glass, B., Sureda, A., Boumendil, A., Dreger, P., Corradini, P., Ram, R., Kroeger, N., Castagna, L., Pabst, T., Kwon, M., Wulf, G., García‐Sancho, A. M., Solano, C., Stelljes, M., Reinhardt, H. C., Rubio, M. T., Malladi, R., Blaise, D., Besley, C., Forcade, E., Bonin, M., Struessmann, T., Hilgendorf, I., Martínez‐López, J., Perez‐Simon, J. A., Bethge, W., Schmitz, N.
Format: Article
Language:English
Subjects:
B-cell lymphoma
Cell therapy
Lymphoma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.3164_331